OncoBayes Advances OB-001 to Combat Resistance in Cancer Therapies

OncoBayes Makes Significant Strides With OB-001 Development

OncoBayes, a clinical-stage private pharmaceutical company, has proudly announced the completion of its preclinical development of OB-001, a promising new drug that aims to address critical unmet needs in oncology. Specifically, OB-001 is designed to combat the resistance seen with antibody-drug conjugates (ADCs) and improve the entry of tyrosine kinase inhibitors (TKIs) into the brain. This could be a game-changer for patients battling cancers that have traditionally proven difficult to treat due to these challenges.

What is OB-001?

OB-001 functions as a highly selective and effective inhibitor of two key efflux pumps: P-glycoprotein and Breast Cancer Resistant Protein (BCRP). These pumps play significant roles both at the blood-brain barrier and on tumor cells, hampering the effectiveness of many cancer treatments. The innovative formulation of OB-001 is a once-daily oral tablet, designed for use in conjunction with various reference oncology therapies to maximize treatment efficacy.

Recent preclinical tests involving brain-perfused mice have yielded compelling results, demonstrating that pre-treatment with OB-001 significantly enhanced cerebral exposure to four reference kinase inhibitors without altering systemic plasma concentrations. At a recent conference of the American Association for Cancer Research (AACR) in 2026, it was reported that OB-001 could lead to nearly a 400% increase in brain exposure to osimertinib, with minimal systemic modifications. This enhancement is expected to result in a meaningful improvement in progression-free survival for non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations. Controlling brain metastases remains a significant unmet need in NSCLC and breast cancer management, emphasizing the importance of this research.

Addressing Monoclonal Antibody Resistance

Beyond its role with TKIs, OB-001 has emerged as a potential solution to the significant issue of resistance to monoclonal antibody treatments. The overexpression of efflux pumps is a major mechanism of resistance, which reduces the concentration of active drug within tumors. Preclinical data from bidirectional transport assays have demonstrated that OB-001 minimizes the efflux of several major active compounds, including SN-38 (as seen with sacituzumab govitecan), DM4 (mirvetuximab soravtansine), and DXd (trastuzumab deruxtecan).

In response to these promising findings, OncoBayes is gearing up for a parallel clinical trial program aimed at generating proof-of-concept data for OB-001 in combination with osimertinib and exploring the potential for re-sensitizing patients to trastuzumab deruxtecan.

Jim Millen, the CEO of OncoBayes, expressed his enthusiasm, stating, "This is a pivotal moment for our team, as we are on the brink of initiating clinical trials with OB-001. OB-001 is poised to become a pioneering drug in its class, offering a broad potential as a simple oral adjuvant to a variety of leading oncology therapies. This pipeline opens real commercial opportunities."

With the promise of OB-001 significantly on the rise, the pharmaceutical landscape may soon witness transformative changes in treating resistant cancers, ultimately enhancing patient outcomes and quality of life.